Skip to content
    Clinical Trials

    Prognostic Value of Patient-Reported Outcomes for PFS and OS in Advanced Gastric/GEJ Cancer

    Moehler et alQuality of Life Research

    Prognostic Value of Patient-Reported Outcomes for PFS and OS in Advanced Gastric/GEJ Cancer
    In the RATIONALE-305 trial (NCT03777657), tislelizumab plus chemotherapy previously improved overall survival (OS) compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) across the intention-to-treat population and in patients with a programmed death-ligand 1 (PD-L1) tumor area positivity (TAP) score ≥ 5%.
    To assess the relationship between patient-reported outcomes (PROs) and clinical survival outcomes, investigators developed a three-component joint model analyzing longitudinal PRO data from the EORTC QLQ-C30 and QLQ-STO22 instruments. The model integrated: (1) a linear mixed model (LMM) for change from baseline in PRO scores; (2) a Cox model for time to recurrent symptomatic deterioration (RS-D); and (3) a Cox model assessing RS-D event frailty prediction of progression-free survival (PFS) and OS.
    The analysis included 475 patients in the PD-L1 TAP score ≥ 5% subgroup, with 238 receiving tislelizumab plus chemotherapy and 237 receiving placebo plus chemotherapy. In the PFS and OS LMMs, the tislelizumab regimen was associated with improved global health status/quality of life (GHS/QoL; p = 0.01) and reduced dietary restrictions (p = 0.05). In the OS LMM specifically, tislelizumab was associated with lower dietary restrictions (p = 0.02) and fewer upper gastrointestinal symptoms (p = 0.01). RS-D events in GHS/QoL, pain, and dietary restrictions emerged as primary predictors of PFS risk. Across all assessed QLQ-C30 and QLQ-STO22 domains, tislelizumab plus chemotherapy significantly reduced the risk of disease progression or death (PFS hazard ratios [HR] 0.55–0.65, representing a 35%–45% reduction) and death (OS HR 0.65–0.73, representing a 27%–35% reduction), with all comparisons reaching p ≤ 0.01. The authors conclude that PROs hold significant prognostic value for survival and disease progression in advanced GC/GEJC with PD-L1 TAP score ≥ 5%.

    Key Takeaways

    • Across all EORTC QLQ-C30 and QLQ-STO22 domains, tislelizumab plus chemotherapy significantly reduced the risk of progression or death (PFS HRs 0.55–0.65; 35–45% reduction) and death (OS HRs 0.65–0.73; 27–35% reduction) compared to placebo plus chemotherapy (all p ≤ 0.01).
    • Tislelizumab plus chemotherapy was associated with improved global health status/quality of life (p = 0.01) and reduced dietary restrictions (p = 0.05 in PFS and OS models; p = 0.02 in the OS model), as well as reduced upper gastrointestinal symptoms (p = 0.01).
    • Recurrent symptomatic deterioration in global health status/quality of life, pain, and dietary restrictions were identified as leading predictors of progression-free survival risk.
    Read the original sourceQuality of Life Research